Immunovant (IMVT) CTO Jay S Stout Sells $75K of Stock

Immunovant, Inc. Chief Technology Officer Jay S. Stout sold 2,595 shares of the company on October 21, 2026, according to a Form 4 filing with the U.S. Securities and Exchange Commission.

IMVT Immunovant, Inc.

$28.41 ▲ +9.65% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Inside Jay S. Stout's Immunovant Trade

Stout executed the sale at a price of $28.94 per share, bringing the total value of the transaction to $75,099.30. Following the sale, the executive directly holds 198,937 shares of the biotechnology firm. The change represents a 1.29% reduction in his overall position. The trade was not carried out under a pre-arranged Rule 10b5-1 trading plan. On the day of the transaction, Immunovant shares closed at $28.38.

Other Institutional Activity in Immunovant

Large investment firms have adjusted their holdings in the biotech company over recent quarters. Farallon Capital Management grew its holdings by 1,534,000 shares, ending with 1,546,000 shares worth about $59,567,378. Deep Track Capital, LP reduced its stake by 2,185,442 shares to finish with 9,341,151 shares valued at roughly $265,382,098. Farallon Capital Management LLC grew its holdings by 4,259,020 shares, ending with 5,805,000 shares worth about $164,920,049. Baker Bros. Advisors, LP reduced its holdings by 22,924 shares, ending with 5,435,220 shares worth roughly $154,414,599. Two Seas Capital LP grew its holdings by 1,464,097 shares, ending with 4,612,692 shares valued at about $131,046,579.

Immunovant, Inc. Stock Up 0.1%

The shares recently traded around $28.41 as of October 23, 2026, which is about equal to the closing price on the transaction date. The stock has traded between a 52-week low of $18.51 and a 52-week high of $45.42.

Recent Earnings

The company reported a trailing twelve-month earnings per share of -$2.82. The firm maintains a return on equity of -80.1%.

Insider Buying and Selling at Immunovant, Inc.

Prior insider transactions at the company include sales by several executives and directors. Director Atul Pande sold 1,500 shares on July 24, 2026, at $39.80 per share for a total of $59,700. Chief Operating Officer Melanie Gloria sold 3,056 shares on August 20, 2026, at $44.16 per share for a total of $134,953. Director Atul Pande sold another 1,500 shares on August 28, 2026, at $43.27 per share for $64,905. Chief Executive Officer Eric Venker sold 3,506 shares on October 2, 2026, at $34.11 per share for a total of $119,590.

Analysts Set New Price Targets

Wall Street firms continue to update their views on the stock. Citigroup maintained a buy rating with a $61.00 price target on June 30, 2026. JP Morgan maintained an overweight rating with a $50.00 price target on August 4, 2026.

About Immunovant

Immunovant, Inc. is a clinical-stage biotechnology company based in Durham, North Carolina. The firm develops targeted therapies to treat autoimmune diseases. Its pipeline includes IMVT-1402, a monoclonal antibody intended to inhibit neonatal fragment crystallizable receptors for various conditions such as Graves' disease and rheumatoid arthritis.

Bottom Line

Executive trades offer a window into how leadership manages personal equity holdings, though they do not necessarily reflect shifts in corporate direction. Investors often review these regulatory filings alongside broader institutional ownership trends and upcoming clinical milestones.